Loading
A phase 1/2 trial of Gemcitabine, Paclitaxel / nab-paclitaxel in pancreatic ductal adenocarcinoma, run by Nelum Corp, active and no longer recruiting.
Study to Evaluate the Safety and Efficacy of Treatment With NLM-001 and Standard Chemotherapy Plus Zalifrelimab in Patients With Advanced Pancreatic Cancer is a phase 1/2 interventional study registered as NCT04827953 by Nelum Corp, with 28 participants enrolled, started 2021-09-01 and due to reach its primary completion in 2025-04. Interventions recorded: Gemcitabine, Nab paclitaxel, NLM-001, Zalifrelimab. Conditions listed: Pancreatic Ductal Adenocarcinoma. No results are recorded here; the registry entry is the source.